from thrombotic, necrotic and hemorrhagic areas, 8, 9 these species can generate the highly reactive hydroxyl radical by Fenton chemistry (Figure 1 ). 7, 10 This radical can initiate the process of lipid peroxidation which, if uncontrolled, may result in endothelial-cell damage, as hypothesized by Hubel and colleagues. 6 Extracellular hemoglobin can also support lipid peroxidation either through prior iron release or release of heme from methemoglobin. 9, 10 Free heme can generate lipid hydroperoxides in low density lipoprotein (LDL) particles 11 or diffuse into membranes of endothelial cells causing peroxidative damage and cytotoxicity. 12 Even minimal vascular hemolysis is sufficient to yield hemoglobin at a concentration range that can affect LDL peroxidation.
Protection from these deleterious pro-oxidative effects in the plasma is normally afforded by proteins that bind these iron entities in a relatively inert state. Plasma iron is usually almost entirely safely bound to the transport protein transferrin. The greater the extent to which transferrin is saturated with iron, the lower the antioxidant capacity of the plasma. 13 Iron released intracellularly is normally safely sequestered in ferritin and serum ferritin reflects the amount of the storage protein.
6 iron parameters, including hemopexin, serum ferritin and the extent to which transferrin is saturated with iron, in pre-eclamptic women and matched pregnant controls.
Material and methods
Forty obstetric patients at the John Radcliffe Hospital, Oxford, identified as suffering from pre-eclampsia according to specific criteria (new hypertension, from below to consistently at or above 90 mm Hg diastolic pressure; new proteinuria ≥ 75 mg / mmol creatinine, in the absence of urinary-tract infection), were each matched with a healthy pregnant woman of the same age ± 4 years, the same gestation ± 13 days and the same parity group namely 0, 1-3 or ≥4. All controls had conceived spontaneously, had never received a blood transfusion and were not on any medication. . The pre-eclamptic patients received treatment for their blood pressure, methyl dopa and/or nifedipine. Neither pre-eclamptic nor control women received iron supplements. Serum was prepared from venous blood collected from these women and stored at -40 0 C until analyzed. The mean gestational age at the time of blood sampling was 33 weeks. Samples were obtained in two sets of 20 pairs in consecutive years. Ferritin was determined only in the first set of 20 pairs, while an electrophoretic technique not initially available to us, was applied only to the second set of 20 pairs, to determine percent-transferrin-saturation, apotransferrin and hemopexin. One control sample from the first set was lost giving 19 pairs for statistical analysis.
The clinical characteristics recorded were:-age, gestational age at the time of blood sampling, systolic and diastolic blood pressure, proteinuria, platelet count, aspartate aminotransferase (AST) activity (an indicator of liver damage), gestational age at the time of delivery, infant sex and birth weight. 18 This method separates transferrin into the apo-, the two monoferric forms and the diferric form, according to their electrophoretic mobilities. To enable detection of the four transferrin bands, serum samples were treated before being applied to the gel with 6,9-diamino-2-ethoxyacridine lactate (Sigma Chemical Co., UK) to precipitate all serum proteins but β-and γ-globulins. On completion of the electrophoretic run, the gel was stained for 20 min and then repeatedly destained until the background was clear. The relative amounts of the transferrin components were determined by densitometry using the Oast Tech computer Serum ferritin was determined by a microparticle enzyme immunoassay method using the Abbott AxSYM system (Abbott Laboratories, Diagnostics Division, Maidenhead, UK).
The recommended quality control procedures of the manufacturer were carefully followed.
Data Analysis. Owing to some extremely high values, parametric statistical methods appropriate for normally-distributed data were precluded. Wilcoxon's Signed Rank Test for non-parametric, paired data was used to compare iron parameters in the pre-eclamptic patients and their matched controls. Infant birth weights were allocated to centiles using "Oxford Standards" charts (Castlemead, Ware, Herts., UK), allowing correction for length of gestation and sex. The χ 2 test was then applied to compare the frequency distribution of centile birth weights in the pre-eclamptic and control groups. Linear regression analysis was used to identify possible correlations between the different iron parameters measured and the clinical data (e.g. gestational age, AST activity, platelet count, systolic or diastolic blood pressure). For all tests significance was accepted for p < 0.05.
Results
The pre-eclamptic patients were all suffering from a fairly severe to very severe level of the disease. Ten had AST levels > 42 IU/l suggesting a component of liver damage while thirteen had a low platelet count (< 175x10 9 cells/l), also indicative of disease severity, though two control subjects also had a platelet count in this range. Seven of the pregnancies were complicated by the HELLP (hemolysis, elevated liver enzymes, low platelets) or ELLP (elevated liver enzymes, low platelets) syndromes. Gestational age at delivery and centile infant birth weights (corrected for length of gestation and sex) were significantly lower (p < 0.0001 and 0.001 respectively) in the pre-eclamptic group, the latter indicating some fetalgrowth retardation. Median hematocrit did not differ between the groups.
For all parameters measured, results, including maximum and minimum values and interquartile ranges, are summarized in Table 1 .
Median serum iron concentration was around 1.7 fold higher in patients with preeclampsia than in pregnant controls (21.7 vs 12.9 µmol/l; p < 0.001). Results are shown graphically in Figure 2 . Of the pre-eclamptic subjects, four had very high values for serum iron (43.7 -79.3 µmol/l) and their AST levels indicated liver damage. Omission of these subjects from the analysis reduced the ratio of the median serum iron concentrations from 1.7 to 1.5 (p < 0.001).
Both UIBC and TIBC were significantly lower in the pre-eclamptic patients than in the matched controls (47.5 vs 68.7 µmol/l; p < 0.0001) and (75.5 vs 85.7 µmol/l; p < 0.0001) respectively.
Median percent saturation of iron-binding capacity (colorimetric method) in women with pre-eclampsia was twice as high as that of matched controls (32.2% vs 15.9 % ; p < 0.0001). Four pre-eclamptic subjects with elevated AST levels had values for percent saturation of iron-binding capacity of 50-100%. Even when these subjects were excluded from the analysis, iron-binding capacity was still 1.8 times more saturated in the preeclamptic patients than in controls. Seven of 40 pre-eclamptic patients (18%) had percent saturation levels in the range associated with iron overload states (50-100%). 14 Percent saturation of transferrin (electrophoretic method), was more than twice as high in the preeclampsia group as in the normal-pregnancy group (median: 27.6 % vs 11.6%; p<0.0001).
Two of 20 pre-eclamptic patients (10%) had percent saturation levels in the range associated with iron overload states.
Since transferrin is by far the most important iron binding protein in serum, 19 determination of the percent saturation of iron binding capacity as measured by the colorimetric method is to a good approximation a determination of the percent saturation of transferrin as obtained directly by gel electrophoresis. Indeed there was a highly significant correlation, between the two methods for both patient groups (r = 0.94 for combined data; p<0.0001).
Apotransferrin level measured in arbitrary units was significantly lower in preeclampsia patients than in matched pregnant controls (289 vs 530; p<0.0001).
Hemopexin level measured in arbitrary units in the pre-eclampsia group did not differ significantly from the hemopexin level in the normal pregnancy group (257 vs 237).
Median serum ferritin was around six-fold higher in the pre-eclamptic patients than in the matched pregnant controls (53.1 vs 9.4 µg/l; p<0.001) as shown graphically in Figure 3 .
Three out of four subjects with very high ferritin levels (257-1259 µg/l) had AST values > 42 IU/l, suggesting a component of liver damage. When those subjects were excluded however, the median ferritin level was still about five-fold higher.
No significant correlations were found between serum iron, TIBC, UIBC, 
Comment
The colorimetric and electrophoretic methods used to gauge the extent of transferrin saturation with iron in our subjects gave results which were very significantly correlated and indicated that transferrin saturation in the pre-eclamptic patients was double or more, that in the controls. This reflects the significantly higher serum iron (by 68%) and significantly lower total iron binding capacity, TIBC (by 12%), of the pre-eclamptic subjects compared to the controls. Seven of the 40 pre-eclamptic subjects (18%), had percent saturation levels within the range associated with iron overload.
significantly decreased (by 31%) in the pre-eclamptic group relative to the control group.
This suggests that pre-eclamptic women only have around two-thirds of the capacity of controls to bind additional iron. UIBC reflects the concentrations of both apotransferrin and mono-ferric transferrin species. Apotransferrin alone, measured by the electrophoretic method, was decreased even further than UIBC -by 45% -in the pre-eclamptic group relative to the control group, reflecting the decreased likelihood of finding any iron-free transferrin at the much-higher iron concentrations existing in this group.
Our findings on iron, UIBC, TIBC and % saturation of iron-binding capacity are in agreement with those of previous studies. 8, 13, 16, 17 The lack of correlation between serum iron and AST levels reflects the poor correlation with parameters of hepatocellular injury found previously 16, 17 and suggests that the raised iron levels cannot be explained by liver damage.
Hemopexin levels, monitored as an indirect measure of whether heme release could be a factor in stimulating lipid peroxidation, were not significantly different in pre-eclamptic patients and their normal pregnant controls. As levels of hemopexin do not always decrease in states of intravascular hemolysis, 20 there remains the possibility of some release of heme into the circulation in pre-eclampsia, particularly as increased levels of heme metabolites are certainly observed. 8 Furthermore, since it was not possible to separate apohemopexin and heme-hemopexin on the urea-polyacrylamide gel, a difference in the heme bound would not have been detected.
Previous studies have come to different conclusions about whether ferritin levels are raised in pre-eclampsia. 16, 17 In our study, even when the three subjects with very high ferritin
and AST values were excluded from the analysis, the median ferritin level was still around five-fold higher in the pre-eclamptic group and no correlation was found between serum ferritin and AST levels. This suggests that liver damage is not the principal source of the raised ferritin levels in most subjects, corroborating previous findings. 21 Ferritin is an acute-phase protein. The highest levels of ferritin, an acute phase protein, were not found in subjects with the lowest albumin levels, suggesting that an acute-phase response was not responsible for the raised serum ferritin. Serum ferritin was not correlated with serum iron, in line with findings from previous workers. 21 Gestational age at the time of sampling was significantly and positively correlated with TIBC and weakly with UIBC, but only in the pre-eclampsia group. This correlation was not observed in the control group though it might have been expected as a response to falling iron levels as the pregnancy progressed. 22 Hubel and colleagues did not observe a correlation between TIBC and gestational age in pre-eclampsia. 13 We cannot explain our findings or the difference between the two studies, except to postulate that a mechanism may exist for increasing transferrrin expression in response to oxidative stress.
Origin of increased serum iron.
The lack of correlation with parameters of liver injury in this and other studies eliminates the liver as the probable source of iron. 20 However, data are consistent with a rise in heme catabolism following increased destruction of maternal red cells 8, 13, 16, 17 and a nine-times greater level of hemoglobin in the serum of pre-eclamptic than control subjects has been reported. 17 The pre-eclamptic placenta presents a histological picture of severe vascular damage in decidual vessels adjacent to infarcted areas, 23 consistent with cell injury and release of iron. Injured red blood cells from necrotic and hemorrhagic areas of infarcted or ischemic placental tissue may be a primary source of potentially toxic iron through the release of hemoglobin or heme into the system. 8, 9 Is iron involved in the etiology of pre-eclampsia? Oxidative stress in pre-eclampsia correlated inversely with UIBC and positively with % transferrin saturation. 13 This implies that iron (or an iron species) could be a factor in the generation of the oxidative stress of the condition. Even at very low concentrations, iron entities such as hemoglobin and heme can increase LDL oxidation, 11 suggesting a further mechanism by which iron might be involved in the etiology of the condition. The ability of vitamins C and E to decrease LDL oxidation might explain their effectiveness in reducing the risk of pre-eclampsia. 24 The damaged placenta is a likely site for the production of free radicals in preeclampsia. Iron species released there from red-cell destruction are clearly capable of initiating and propagating lipid peroxidation 25 both in the placenta and in the vasculature, and may be a significant etiological factor in the endothelial-cell damage of pre-eclampsia.
Conclusion.
This work has highlighted a significant deficit in the antioxidant capacity of serum by decreased serum-iron buffering in pre-eclampsia. Released iron species may be implicated in the etiology of the condition, but at the very least, are likely to increase oxidative stress, exacerbate lipid peroxidation and promote endothelial-cell injury.
We concur with the previous suggestion 22 that raised serum iron and ferritin may have the potential to be used diagnostically to warn of incipient pre-eclampsia.
Eighteen percent of our pre-eclamptic subjects had transferrin saturation levels in the region associated with iron overload. It is now known that as many as 38% of the population are at increased risk of iron overload owing to mutations in the HFE gene associated with haemochromatosis. 26 Given the prevalence of heterozygosity for hemochromatosis with the associated reduced ability to exclude ingested iron, 26, 27 and the proportion of our pre-eclamptic subjects with iron overload, it may be appropriate to consider the advisability of giving iron supplements to pregnant women at high risk of pre-eclampsia, in the absence of evidence of iron deficiency. While there is no suggestion that iron supplements are the cause of the excess iron seen in pre-eclampsia, they could be an exacerbating factor in women susceptible to iron overload. Accordingly, the same strictures would apply to the use of parenteral iron.
Genetic evaluation of mutations in the HFE gene in a larger study of such women would be of interest. 
